RNA bundled in lipid nanoparticles trains T cells in mice to eliminate cancer. Coupled with noninvasive imaging, researchers tracked the in situ CAR-T cells to assess their effectiveness and safety.

Mayo Clinic researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T ...

During a live event, Jorge Monge, MD, discussed short and long-term adverse events associated with CAR T-cell therapy in ...

Study identifies proximity-based mechanism behind LAG-3 inhibition and introduces novel bispecific antibody for autoimmune ...

A team of physicians recently reported the successful treatment of refractory autoimmune neuropathies through the infusion of autologous anti-CD19 CAR T-cells.

Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case o ...

Chimeric Antigen Receptor (CAR) T Cells Releasing Soluble SLAMF6 Isoform 2 Gain Superior Anti-Cancer Cell Functionality in an Auto-Stimulatory Fashion, Cells, 14, 12, (901), (2025). https://doi ...

A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and ...

Giving an additional receptor to T cells that might already be targeting cancer naturally might also “over-activate” those cells, leading to quicker exhaustion of immune cells.